International Immunopharmacology SCISCIE

International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.

The subject material appropriate for submission includes:

• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.

• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.

• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.

• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.

• Agents that activate genes or modify transcription and translation within the immune response.

• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.

• Production, function and regulation of cytokines and their receptors.

• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.

国际免疫药理学是发表与免疫学、药理学、细胞因子生物学、免疫疗法、免疫病理学和免疫毒理学重叠领域相关的原创研究论文的主要载体。也欢迎包含这些主题的评论文章。

适合提交的主题材料包括：

• 采用任何类型的免疫疗法的临床研究，包括使用：细菌和化学试剂；胸腺激素、干扰素、淋巴因子等，用于移植和癌症、免疫缺陷、慢性感染和过敏、炎症或自身免疫性疾病等疾病。

• 研究这些药物对特定免疫能力参数以及整体临床状态的作用机制。

• 关于免疫增强剂、免疫调节剂、免疫佐剂和其他对参与免疫或过敏反应的细胞具有活性的药物作用机制的临床前动物研究和体外研究。

• 影响淋巴系统的药理化合物、微生物产品和毒物及其作用机制。

• 在免疫反应中激活基因或修改转录和翻译的试剂。

• 通过具有药理活性的免疫或相关途径激活、产生或释放的物质。

• 细胞因子及其受体的产生、功能和调节。

• 关于免疫反应过程中释放的趋化因子和生物活性因子影响的经典药理学研究。

该刊已被国际权威数据库SCI、SCIE收录，是国际顶级期刊。该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-免疫学领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2022年影响因子为5.6，平均审稿速度为约2.7个月，近三年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。